Skip to main content
. 2022 Jul 16;127(7):1304–1311. doi: 10.1038/s41416-022-01913-4

Table 2.

Comparison of Copy-number variation (CNV) characteristics of patients with microsatellite stable (MSS) cancers in early- and late stage.

Cytoband/gene Early stage, n = 233 Late stage, n = 239 P value
08q22.3/UBR5 gain 0.0575
 Yes 14 (6.0%) 26 (10.9%)
 No 219 (94.0%) 187 (89.1%)
08q24.21/MYC gain 0.0107
 Yes 17 (7.3%) 35 (14.6%)
 No 216 (92.7%) 204 (85.4%)
08q22.1/CCNE2 gain 0.0700
 Yes 16 (6.9%) 28 (11.7%)
 No 217 (93.1%) 211 (88.3%)